Chronic obstructive pulmonary disease (COPD) is a frequent comorbid condition associated
with increased morbidity and mortality. Pneumonia is the most common infectious disease …

Background Pneumonia may be a major contributor to hospitalizations for chronic
obstructive pulmonary disease (COPD) exacerbation and influence their outcomes. Methods …

Rationale: Mucosal-associated invariant T (MAIT) cells are a recently described abundant,
proinflammatory T-cell subset with unknown roles in pulmonary immunity. Nontypeable …

Asthma is a complex, heterogeneous condition that affects over 350 million people globally.
It is characterised by bronchial hyperreactivity and airways inflammation. A subset display …

Clinical phenotyping is currently used to guide pharmacological treatment decisions in
chronic obstructive pulmonary disease (COPD), a personalized approach to care. Precision …

The nonrecognition of asthma-associated comorbidities is often responsible for the
therapeutic failure and the worsening of symptoms, and it is associated with frequent …

In recent years, heterogeneity in chronic obstructive pulmonary disease (COPD)
inflammatory patterns has been recognized as a basis for more precise treatment …

ABSTRACT RATIONALE: Since the last published Canadian Thoracic Society (CTS) COPD
guideline in 2007 and the 2008 update–highlights for primary care, many new clinical trials …

Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler
fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced …

Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity and
mortality in the world. Regrettably, there are no biomarkers to objectively diagnose COPD …